Regencell Bioscience Holdings Limited (RGC)
| Market Cap | 7.17B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.09M |
| Shares Out | 494.49M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 644,216 |
| Open | 15.60 |
| Previous Close | 14.86 |
| Day's Range | 14.15 - 15.60 |
| 52-Week Range | 0.08 - 83.60 |
| Beta | 2.28 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jun 30, 2025 |
About RGC
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. The company focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. Regencell Bioscience Holdings Limited was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
This Chinese Herb Stock Is Now Bigger Than Super Micro And Reddit
Regencell Bioscience Holdings Ltd. RGC, a Hong Kong-based biotech startup with no reported revenue, has gained more than 59,000% in 2025.
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
This stock with no revenue surges 64,000% in a year: find out why
Regencell Bioscience Holdings, a biotech company focused on herbal medicine, has gained over 400% on Monday and over 64,000% in the past year. This growth in stock price is despite the company not hav...
Regencell Bioscience's Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial
HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (Nasdaq: RGC) (“Regencell”) today announced its interim results from its second efficacy trial. Regencell conducted its...
Slow And Steady Wins The Race With Regencell Bioscience
Regencell Bioscience is an early-stage bioscience company focused on the research, development, and commercialization of Traditional Chinese Medicine. Regencell Chairman and CEO, Yat-Gai Au recently p...
Sector Rotation And 9 Stocks To Watch During A Recession
Is the United States heading toward a recession? This has been the looming question on the minds of Americans since inflation topped at 8.5% in March, matched with other indicators such as rising inte...
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period
HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (NASDAQ: RGC): Results of EARTH efficacy trial EARTH Efficacy Trials Period of trial 30 January 2022 – 31 March 2022 ...
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO
HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research, development a...
Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network
LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holding...
Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate Symptoms
Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the results from the EARTH efficacy trial of its COVID-19 candidate. RGC-COV19 (Regencell Bioscience (RGCA-CV01) liquid formulation) is an...
Regencell Bioscience's Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial
HONG KONG--(BUSINESS WIRE)---- $RGC #ADHD--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”) today announced the results from an analysis of a total of 37 individuals ...
Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors
HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercializa...
Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO
HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercializa...
Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index
HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercializa...
Regencell Bioscience Stock Jumps On Formation Of COVID-19 Treatment Focused Joint Venture
Regencell Bioscience Holdings Ltd's (NASDAQ: RGC) subsidiary in Hong Kong has entered into a joint venture agreement with Honor Epic Enterprises Limited to offer COVID-19 related treatments. The joint...
Regencell Bioscience Holdings Limited Establishes a Joint Venture to Offer COVID Treatment
HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), today announced that Regencell Bioscience Limited (“Regencell HK”), the Company's wholly...
Regencell Bioscience Holdings Limited Announces Partial Exercise of Underwriter's Over-Allotment Option
HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) ("Regencell" or the "Company"), an early-stage bioscience company that focuses on research, development and commercializa...
Regencell Bioscience Holdings Limited Releases CEO Letter to Shareholders
HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company today released a letter from Yat-Gai Au, Founder and C...
Regencell Bioscience Holdings Limited Announces Closing of Initial Public Offering
HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercializa...
7 Companies Begin Trading. Here's How They're Doing.
The group is diverse—a fintech, three biotechs, a real-estate investment manager, a bioscience company, and a pharmaceutical glassmaker.
Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering
HONG KONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) (“Regencell” or the “Company”), an early-stage bioscience company that focuses on research, development and commercializa...